
https://www.science.org/content/blog-post/fishing-around-biomarkers
# Fishing Around for Biomarkers (January 2011)

## 1. SUMMARY

The 2011 article discusses the long-standing challenge of finding predictive biomarkers for human diseases—simple, reliable tests that correlate with disease course or treatment response. It highlights the difficulty of searching for relevant antibodies in a haystack of roughly ten billion different antibodies per person, especially when the target antigens are unknown (a chicken-and-egg problem). Conventional approaches include directly hunting for unusual molecules in patient tissue samples.

The piece focuses on a *Cell* paper that took a different path: synthesizing thousands of “peptoids” (poly-glycines with anomalous N-substituents), arraying them, and probing serum from disease models. In a rodent model of multiple sclerosis (EAE), the array successfully pulled down disease-specific antibodies with good time-course correlation and little cross-reactivity. When applied to Alzheimer’s disease, the peptoid array differentiated AD patients from controls and Parkinson’s/lupus patients in blinded samples, though with two control “outliers” that could reflect pre-symptomatic disease. The authors were extending the work to wider populations and seeking native antigens; the commentary saw it as a promising, if early, step.

## 2. HISTORY

The peptoid microarray approach described in the 2011 article did not translate into a broadly adopted, FDA-approved diagnostic or therapeutic biomarker platform for Alzheimer’s or multiple sclerosis in the subsequent decade-plus. Key developments after 2011 include:
- **Amyloid PET imaging** became a validated biomarker for cerebral amyloid pathology, enabling enriched clinical trials and, eventually, tying anti-amyloid therapies to amyloid clearance as a surrogate endpoint.
- **CSF biomarkers** (Aβ42/40, p-tau181, t-tau)—already emerging pre-2011—solidified into the AT(N) framework and became part of diagnostic guidelines, alongside plasma versions that achieved clinical-grade performance after ~2017 via mass spectrometry and immunoassays.
- **Plasma p-tau217 and p-tau181** emerged as highly specific blood-based biomarkers for AD, achieving high performance in distinguishing AD from controls and predicting amyloid/tau PET status; recent work supports their utility for screening and monitoring.
- **Anti-amyloid therapies** (e.g., aducanumab, lecanemab) achieved accelerated or traditional FDA approval tied to biomarker-based enrichment and endpoints (PET amyloid reduction; plasma biomarkers showed promise for monitoring).
- **MS biomarker evolution** was dominated by established MRI lesion metrics and CSF oligoclonal bands; efforts to validate additional blood biomarkers (e.g., neurofilament light) advanced but did not rely on peptoid arrays.
- **Infectious disease diagnostics** shifted toward PCR/antigen tests and CRISPR-based detection; **cancer liquid biopsy** accelerated with ctDNA/CTC approaches and methylation profiling.

Notably, a commercially successful, widely deployed blood diagnostic built on peptoid microarrays did not materialize, nor did therapies guided by peptoid-discovered biomarkers enter routine clinical practice. The peptoid-array technique remained an experimental proteomics tool rather than a clinical platform. Two companies mentioned alongside this strategy around that time (Nerviano Medical Sciences; the Cell work out of Scripps) did not drive subsequent approvals or large-scale uptake from this technology.

## 3. PREDICTIONS

- **Implicit prediction: Peptoid arrays could evolve into a practical AD diagnostic**.
  - Actual outcome: Clinical AD diagnostics standardized around PET imaging, CSF Aβ/tau, and subsequently plasma p-tau assays. Peptoid arrays did not become part of the validated AD diagnostic toolkit.
- **Implicit prediction: The two “outlier” control samples with raised antibody signals might reflect pre-symptomatic AD**.
  - Actual outcome: Without long-term follow-up published to validate pre-symptomatic AD in those samples, this remains speculative. Epidemiologically, 2/16 controls (~12.5%) would be higher than typical population amyloid positivity in that era, so it is unknown whether this represented true preclinical disease or false positives.
- **Implicit prediction: The technique could be applied to other diseases**.
  - Actual outcome: Peptoid microarrays continued to be used in proteomics research for epitope discovery and antibody profiling but did not yield widely adopted diagnostics for MS, cancer, or major autoimmune diseases. Alternative platforms dominated the liquid biopsy and immunoassay space.

## 4. INTEREST

Rating: **4/10**
The article is historically instructive about biomarker-discovery efforts circa 2011 but did not anticipate the pathways that actually succeeded in AD and MS diagnostics (AT(N) framework, plasma p-tau) or commercial deployment. The peptoid microarray avenue did not translate into clinical or regulatory success.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20110114-fishing-around-biomarkers.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_